mRNA Technology Newsletter
Issue #36May 11, 20267 studies

Fractalkine-targeted mRNA nanoparticles hit 95% of killer T cells in mice

This week brought major advances in mRNA delivery precision, with researchers developing new ways to target specific immune cells and overcome the liver-trapping problem that has limited gene therapy applications.

🎯 Precision mRNA delivery hits 95% of target immune cells

  • Scientists developed fractalkine-conjugated mRNA nanoparticles that targeted up to 95% of cytotoxic CD8+ T cells in mouse blood and spleen, and nearly 100% in rhesus macaques

  • The targeted cells successfully expressed new proteins (IL-2 and human CD62L) without affecting their normal function or causing toxicity

  • This represents a breakthrough in selective immune cell reprogramming—previously, mRNA therapies mostly ended up in the liver rather than specific cell types

Why it matters: This could enable precise immune cell modifications for cancer treatment, autoimmune diseases, and other conditions where you need to reprogram specific immune cells without affecting the rest of the body.

🥇 Top 1% journal 🔗 Science immunology Journal Article 🗓️ May 8

Key Findings

🧬 COVID vaccine comparison reveals durability trade-offs

  • A 176-person trial comparing protein-based NVX-CoV2373 with mRNA boosters found that bivalent mRNA vaccines produced the highest early antibody levels (91.7% neutralization vs 84.4% for monovalent mRNA)

  • However, the protein vaccine showed slower antibody decay over 12 months, with better retention (0.51 fold-change vs 0.31-0.35 for mRNA vaccines)

  • All three vaccine types boosted neutralizing antibodies against emerging variants like XBB.1.16 by 1.6-4.1 fold within 28 days

💡 Different vaccine platforms may offer complementary benefits—mRNA for rapid response, protein-based for longer-lasting protection.
Top 20% journal 🔗 Human vaccines & immunotherapeutics Randomized Controlled Trial 🗓️ May 5

🔧 Surface texture controls where mRNA nanoparticles go

  • Researchers discovered that reducing lipid nanoparticle surface hydrophobicity (making them less water-repelling) decreases liver targeting and shifts delivery toward other tissues

  • Less hydrophobic particles showed enhanced targeting of immune cells in the lungs and reduced protein binding in blood plasma

  • Adding quaternary amines increased lung delivery by preferentially targeting lung epithelial cells through distinct protein interactions

💡 Fine-tuning nanoparticle surface properties could unlock mRNA delivery to organs beyond the liver.
🥉 Top 5% journal 🔗 Biomaterials Journal Article 🗓️ May 5

💉 Fractional COVID vaccine doses work as well as full doses

  • A 601-person Mongolian trial found that half-dose (15 μg) BNT162b2 boosters produced comparable antibody and T-cell responses to standard 30 μg doses over 12 months

  • Both doses maintained 89% virus neutralization and similar cellular immunity against wild-type and JN.1 variants

  • Memory T-cell responses peaked at 6 months and remained durable through 12 months for both dose levels

💡 Dose-sparing strategies could stretch vaccine supplies during shortages without compromising protection.
🥉 Top 5% journal 🔗 Frontiers in immunology Randomized Controlled Trial 🗓️ May 8

🦠 Self-amplifying RNA beats regular mRNA for influenza B

  • Self-amplifying RNA (saRNA) vaccines at just 0.1 μg provided complete protection against influenza B virus in mice, while regular mRNA achieved only 14% survival

  • saRNA maintained higher antibody levels over 20 weeks, particularly against influenza B antigens that typically show poor immunogenicity

  • The self-amplifying platform uses viral replicase to continuously produce more antigen inside cells, creating stronger and more durable responses

💡 Next-generation RNA platforms may solve the influenza B vaccine problem that has limited seasonal flu shot effectiveness.
🥉 Top 5% journal 🔗 Emerging microbes & infections Journal Article 🗓️ May 4

🧪 New biodegradable lipids break down faster, work better

  • Scientists designed ionizable lipids with thioester bonds that rapidly degrade in acidic conditions, improving both mRNA delivery efficiency and safety

  • The lead candidate CP-LC-1272 outperformed current clinical standard SM-102 in mRNA expression studies and maintained activity after 6 months of storage

  • These 'thioester-activated ionizable lipids' (TAILs) reduce accumulation risk and could enable safer repeated dosing for chronic conditions

💡 Faster-degrading delivery vehicles could make repeated mRNA treatments safer for long-term therapies.
Top 20% journal 🔗 Pharmaceutics Journal Article 🗓️ May 4

🎯 Lyme disease mRNA vaccine protects mice from tick bites

  • mRNA vaccines encoding Lyme disease protein OspA protected mice against infection in tick-challenge studies, with both single-strain and 7-strain formulations showing efficacy

  • The vaccines produced functional antibodies that promoted bacterial clumping and killing, and adding 6 additional strains didn't interfere with the primary immune response

  • Both monovalent (mRNA-1982) and heptavalent (mRNA-1975) versions are now in Phase 1 human trials

💡 mRNA's flexibility allows rapid design of multi-strain vaccines that could provide broader protection than traditional approaches.
🥉 Top 5% journal 🔗 NPJ vaccines Journal Article 🗓️ May 5

Implications

These studies show mRNA technology maturing beyond COVID vaccines into precision medicine tools. The ability to target specific cell types, tune delivery locations, and create self-amplifying responses suggests we're moving toward more sophisticated therapeutic applications—from reprogramming immune cells to treating genetic diseases.

Studies in this issue

Primary sources used for this newsletter.

  1. Changing killer CD8 T cells inside the body using fractalkine-linked mRNA nanoparticles
    main storyScience immunology2026-05-08PMID 42102231
  2. Immune cell responses one year after full or reduced dose COVID-19 booster in Mongolian adults
    key findingFrontiers in immunology2026-05-08PMID 42099605
  3. Adjusting lipid nanoparticle surface water-repelling properties to control interactions with the body and target mRNA delivery to specific tissues
    key findingBiomaterials2026-05-05PMID 42085855
  4. Different COVID-19 vaccines produce broadly cross-reactive antibodies against new virus variants
    key findingHuman vaccines & immunotherapeutics2026-05-05PMID 42083894
  5. Improved Ionizable Lipids That Break Down Easily and Escape Cell Compartments Better for Delivering mRNA and tRNA
    key findingPharmaceutics2026-05-04PMID 42076124
  6. Stronger immune response and lower dose needed for self-amplifying RNA vaccines against different seasonal flu strains
    key findingEmerging microbes & infections2026-05-04PMID 42081324
  7. Single- and multiple-target OspA mRNA vaccines produce protective antibodies against Lyme disease bacteria in mice
    key findingNPJ vaccines2026-05-05PMID 42086599

Continue reading

All mRNA Technology issues